GGrantIndex
← Search

DEVELOPMENTAL FUNDS (Core 002)

$1,142,799P30FY2020CANIH

Ohio State University, Columbus OH

Investigators

Linked publications, trials & patents

Trial NCT04662645Trial NCT04602026Trial NCT04567706Trial NCT04454086Trial NCT04439006Trial NCT04329962Trial NCT04269837Trial NCT04267874Trial NCT04233567Trial NCT04229381Trial NCT04220684Trial NCT04205903Trial NCT04205240Trial NCT04205071Trial NCT04164069Trial NCT04140513Trial NCT04120454Trial NCT04116970Trial NCT04115163Trial NCT04063410Trial NCT04049539Trial NCT04032106Trial NCT03975231Trial NCT03943342Trial NCT03892044Trial NCT03868423Trial NCT03858855Trial NCT03824327Trial NCT03798639Trial NCT03786354Trial NCT03749018Trial NCT03728361Trial NCT03719092Trial NCT03715959Trial NCT03711890Trial NCT03691350Trial NCT03665675Trial NCT03656835Trial NCT03654638Trial NCT03631641Trial NCT03611205Trial NCT03583424Trial NCT03568526Trial NCT03537599Trial NCT03532581Trial NCT03525925Trial NCT03513562Trial NCT03463460Trial NCT03460483Trial NCT03447808Trial NCT03409432Trial NCT03372720Trial NCT03333746Trial NCT03328936Trial NCT03307044Trial NCT03287453Trial NCT02960100Trial NCT02950220Trial NCT02942524Trial NCT02940301Trial NCT02927899Trial NCT02835755Trial NCT02831582Trial NCT02812693Trial NCT02795104Trial NCT02791737Trial NCT02760030Trial NCT02439255Trial NCT02303392Trial NCT02101944Trial NCT02015117Trial NCT01964924Trial NCT01955499Trial NCT01861314Trial NCT01841723Trial NCT01811212Trial NCT01533194Trial NCT01519414Trial NCT01515176Trial NCT01468896Trial NCT01425879Trial NCT01351896Trial NCT01281124Trial NCT01280058Trial NCT01254617Trial NCT01254578Trial NCT01251874Trial NCT01249430Trial NCT01238133Trial NCT01132586Trial NCT01130506Trial NCT01129193Trial NCT01126502Trial NCT01076556Trial NCT01017640Trial NCT00735930Trial NCT00703300Trial NCT00602277Trial NCT00563290Trial NCT00499473

Abstract

CORE-002: DEVELOPMENTAL FUNDS PROJECT SUMMARY / ABSTRACT In the 2009 CCSG competing renewal, ?Developmental Funds? received a merit descriptor of ?outstanding to exceptional? noting that the use of the funds was extraordinary in terms of the quality of recruitments and leveraging of the developmental funds to the Center's mission. During the current funding period, the OSUCCC benefited from $1,625,283 of CCSG Developmental Funds. For the $1,086,942 of CCSG dollars used for faculty and staff recruitment, the return to-date in total direct costs for CCSG-approved peer-reviewed extramural funding is $45,841,496, a 42:1 return on investment, and in total funding was $47,389,764, a nearly 44:1 return on investment. In addition, we used CCSG funds in the development of two needed and well utilized Shared Resources (SRs), the Medicinal Chemistry SR and the Nutrient and Phytochemical SR, both of which have now transitioned from developing to full Shared Resources and are presented in this application. In the new funding period, we request $2,000,000 in CSSG Developmental Funds over 5 years and propose using this support to continue to focus on building and innovating within our three traditional areas strength: genetics, experimental therapeutics, and prevention. Specifically, we propose to identify and recruit 18 senior, midlevel and junior faculty whose scientific expertise targets relevant needs in the OSUCCC strategic plan and/or catchment area. Further, we propose the development of two shared resources, Solid Tumor Translational Science and the Veterinary Clinical Research Support, that are innovative and necessary to support the science of the Research Programs and their individual member investigators.

View original record on NIH RePORTER →